RU2726631C1 - Гетероциклические спиросоединения в качестве ингибиторов magl - Google Patents

Гетероциклические спиросоединения в качестве ингибиторов magl Download PDF

Info

Publication number
RU2726631C1
RU2726631C1 RU2019123020A RU2019123020A RU2726631C1 RU 2726631 C1 RU2726631 C1 RU 2726631C1 RU 2019123020 A RU2019123020 A RU 2019123020A RU 2019123020 A RU2019123020 A RU 2019123020A RU 2726631 C1 RU2726631 C1 RU 2726631C1
Authority
RU
Russia
Prior art keywords
formula
compound
group
alkyl
pharmaceutically acceptable
Prior art date
Application number
RU2019123020A
Other languages
English (en)
Russian (ru)
Inventor
Майкл Аарон Бродни
Кристофер Райан Батлер
Кристофер Джон Хелал
Лора Энн МАКАЛЛИСТЕР
Стивен Виктор О'Нил
Патрик Роберт ВЕРХУСТ
Original Assignee
Пфайзер Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Пфайзер Инк. filed Critical Пфайзер Инк.
Application granted granted Critical
Publication of RU2726631C1 publication Critical patent/RU2726631C1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/10—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/443—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5386—1,4-Oxazines, e.g. morpholine spiro-condensed or forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/20—Spiro-condensed ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/10—Spiro-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
RU2019123020A 2017-01-23 2018-01-09 Гетероциклические спиросоединения в качестве ингибиторов magl RU2726631C1 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762449242P 2017-01-23 2017-01-23
US62/449,242 2017-01-23
PCT/IB2018/050128 WO2018134698A1 (en) 2017-01-23 2018-01-09 Heterocyclic spiro compounds as magl inhibitors

Publications (1)

Publication Number Publication Date
RU2726631C1 true RU2726631C1 (ru) 2020-07-15

Family

ID=61028112

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2019123020A RU2726631C1 (ru) 2017-01-23 2018-01-09 Гетероциклические спиросоединения в качестве ингибиторов magl

Country Status (14)

Country Link
US (2) US20180208608A1 (https=)
EP (1) EP3571202B1 (https=)
JP (1) JP2020506903A (https=)
KR (1) KR20190097242A (https=)
CN (1) CN110198944A (https=)
AU (1) AU2018208848A1 (https=)
BR (1) BR112019014099A2 (https=)
CA (1) CA3050853A1 (https=)
IL (1) IL267781A (https=)
MX (1) MX2019008690A (https=)
RU (1) RU2726631C1 (https=)
SG (1) SG11201906427QA (https=)
TW (1) TWI665199B (https=)
WO (1) WO2018134698A1 (https=)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA121775C2 (uk) 2015-07-31 2020-07-27 Пфайзер Інк. 1,1,1-трифтор-3-гідроксипропан-2-ілкарбаматні похідні та 1,1,1-трифтор-4-гідроксибутан-2-ілкарбаматні похідні як інгібітори magl
WO2018005865A1 (en) 2016-07-01 2018-01-04 G1 Therapeutics, Inc. Synthesis of n-(heteroaryl)-pyrrolo[3,2-d]pyrimidin-2-amines
EP3571191A1 (en) * 2017-01-20 2019-11-27 Pfizer Inc 1,1,1-trifluoro-3-hydroxypropan-2-yl carbamate derivatives as magl inhibitors
US10927105B1 (en) 2017-05-23 2021-02-23 Lundbeck La Jolla Research Center, Inc. Pyrazole MAGL inhibitors
MX2020007318A (es) * 2017-09-29 2020-08-24 Takeda Pharmaceuticals Co Compuesto heterociclico.
US10662159B2 (en) * 2017-11-22 2020-05-26 Makscientific, Llc ABHD6 and dual ABHD6/MGL inhibitors and their uses
WO2019134985A1 (en) 2018-01-08 2019-07-11 F. Hoffmann-La Roche Ag Octahydropyrido[1,2-alpha]pyrazines as magl inhibitors
AU2019304198A1 (en) * 2018-07-19 2021-02-04 Pfizer Inc. Heterocyclic spiro compounds as MAGL inhibitors
AU2019325685B2 (en) 2018-08-24 2025-07-24 Pharmacosmos Holding A/S Improved synthesis of 1,4-diazaspiro(5.5)undecan-3-one
KR20210069079A (ko) * 2018-09-28 2021-06-10 얀센 파마슈티카 엔.브이. 모노아실글리세롤 리파아제 조절제
MY205440A (en) 2018-09-28 2024-10-21 Janssen Pharmaceutica Nv Monoacylglycerol lipase modulators
AU2019389017B2 (en) * 2018-11-28 2025-01-09 H. Lundbeck A/S Methods of treating disease with MAGL inhibitors
CN109485656A (zh) * 2018-12-17 2019-03-19 上海药明康德新药开发有限公司 3-氧亚基-7-氧杂-2,10-二氮杂螺[4.6]十一烷-10-甲酸叔丁酯的制法
MA54827A (fr) * 2019-01-25 2022-05-04 H Lundbeck As Méthodes de traitement d'une maladie à l'aide d'inhibiteurs de magl
CN114096545A (zh) * 2019-07-09 2022-02-25 豪夫迈·罗氏有限公司 新杂环化合物
JP7697934B2 (ja) 2019-09-30 2025-06-24 ヤンセン ファーマシューティカ エヌ．ベー． 放射線標識されたｍｇｌ ｐｅｔリガンド
WO2021191391A1 (en) * 2020-03-26 2021-09-30 Janssen Pharmaceutica Nv Aminocyclobutanes as monoacylglycerol lipase modulators
CN113966337B (zh) * 2020-05-12 2024-01-02 北京广为医药科技有限公司 调节nmda受体活性的化合物、其药物组合物及用途
MX2023003240A (es) * 2020-09-22 2023-06-16 Janssen Pharmaceutica Nv Moduladores de monoacilglicerol lipasa de ciclobutilamida.
US12029718B2 (en) 2021-11-09 2024-07-09 Cct Sciences, Llc Process for production of essentially pure delta-9-tetrahydrocannabinol
TWI904281B (zh) * 2020-11-13 2025-11-11 丹麥商Ｈ 朗德貝克公司 Magl抑制劑
WO2022135462A1 (zh) * 2020-12-22 2022-06-30 鲁南制药集团股份有限公司 Magl抑制剂的医药用途
CA3242372A1 (en) 2021-12-29 2023-07-06 Psy Therapeutics, Inc. Inhibiting monoacylglycerol lipase (magl)
KR20250005229A (ko) 2022-05-04 2025-01-09 하. 룬드벡 아크티에셀스카브 모노아실글리세롤 리파제 억제제로서 1,1,1,3,3,3-헥사플루오로프로판-2-일 (s)-1-(피리다진-3-일카르바모일)-6 아자스피로[2.5]옥탄-6-카르복실레이트의 결정질 형태
EP4665718A1 (en) 2023-02-13 2025-12-24 Apogee Pharmaceuticals, Inc. Small molecules as monoacylglycerol lipase (magl) inhibitors, compositions and use thereof

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013103973A1 (en) * 2012-01-06 2013-07-11 Abide Therapeutics Carbamate compounds and of making and using same
RU2553451C2 (ru) * 2008-12-24 2015-06-20 Биал-Портела Энд Ка, С.А. Фармацевтические соединения
WO2016149401A2 (en) * 2015-03-18 2016-09-22 Abide Therapeutics, Inc. Piperazine carbamates and methods of making and using same

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0273659A1 (en) 1986-12-27 1988-07-06 Takeda Chemical Industries, Ltd. Azaspiro compounds, their production and use
KR0166088B1 (ko) 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
US5376645A (en) 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
CA2195107A1 (en) 1994-08-02 1996-02-15 Richard Alexander Jelley Azetidine, pyrrolidine and piperidine derivatives
GB9518953D0 (en) 1995-09-15 1995-11-15 Pfizer Ltd Pharmaceutical formulations
WO2000035296A1 (en) 1996-11-27 2000-06-22 Wm. Wrigley Jr. Company Improved release of medicament active agents from a chewing gum coating
GB9711643D0 (en) 1997-06-05 1997-07-30 Janssen Pharmaceutica Nv Glass thermoplastic systems
AU3676100A (en) 1999-04-09 2000-11-14 Mochida Pharmaceutical Co., Ltd. Remedies for neuropathic pain
EP1209974A2 (en) 1999-08-13 2002-06-05 Aventis CropScience GmbH Heterocyclic spiro compounds as pesticides
US20020151712A1 (en) 1999-09-14 2002-10-17 Nan-Horng Lin 3-pyrrolidinyloxy-3'-pyridyl ether compounds useful for controlling chemical synaptic transmission
DE60125980T2 (de) 2000-11-20 2007-10-25 Scios Inc., Sunnyvale P38kinase-inhibitoren vom piperidin/piperazin-typ
CN1264847C (zh) 2001-05-14 2006-07-19 弗·哈夫曼-拉罗切有限公司 1－氧杂－3,9－二氮杂－螺[5.5]十一－2－酮衍生物及其作为神经激肽受体拮抗剂的用途
EP1622569B1 (en) 2003-04-24 2015-12-02 Incyte Corporation Aza spiro alkane derivatives as inhibitors of metallproteases
US7825147B2 (en) 2003-08-29 2010-11-02 Ranbaxy Laboratories Limited Inhibitors of phosphodiesterase type-IV
SE0302811D0 (sv) 2003-10-23 2003-10-23 Astrazeneca Ab Novel compounds
AR046756A1 (es) 2003-12-12 2005-12-21 Solvay Pharm Gmbh Derivados de hidronopol como agonistas de receptores orl-1 humanos.
JP3912400B2 (ja) 2004-03-30 2007-05-09 株式会社デンソー 圧力センサ
ES2370788T3 (es) 2005-02-07 2011-12-22 Aerocrine Ab Controlar flujo de aliento exhalado durante análisis.
EA013646B1 (ru) 2005-05-25 2010-06-30 Басф Акциенгезельшафт Замещённые бензоилом серин-амиды
MX2007014490A (es) 2005-05-25 2008-02-11 Basf Ag Serina amidas sustituidas con heteroaroilo.
MX2007016508A (es) 2005-06-30 2008-03-04 Prosidion Ltd Agonistas del receptor acoplado a la proteina g.
AR055395A1 (es) 2005-08-26 2007-08-22 Vertex Pharma Compuestos inhibidores de la actividad de la serina proteasa ns3-ns4a del virus de la hepatitis c
EP2102208B1 (en) 2006-12-05 2014-04-23 Janssen Pharmaceutica NV Novel substituted diaza spiro pyridinone derivatives for use in mch-1 mediated diseases
FR2915198B1 (fr) 2007-04-18 2009-12-18 Sanofi Aventis Derives de triazolopyridine-carboxamides et triazolopyridine -carboxamides, leur preparation et leur application en therapeutique.
CA2684633A1 (en) 2007-04-20 2008-10-30 Schering Corporation Pyrimidinone derivatives and methods of use thereof
EP2058306A1 (en) 2007-11-08 2009-05-13 Schwarz Pharma Ag Heteroaryl-substituted 2-pyridinyl-methylamine derivatives
MX2011000664A (es) 2008-07-16 2011-02-24 Schering Corp Derivados biciclicos heterociclicos y uso de los mismos como moduladores de gpr119.
MX2011004340A (es) 2008-10-29 2011-05-23 Gruenenthal Gmbh Espiroaminas sustituidas.
WO2010056309A2 (en) 2008-11-14 2010-05-20 The Scripps Research Institute Methods and compositions related to targeting monoacylglycerol lipase
US8415341B2 (en) 2009-04-22 2013-04-09 Janssen Pharmaceutica, Nv Heteroaromatic and aromatic piperazinyl azetidinyl amides as monoacylglycerol lipase inhibitors
JP2012524800A (ja) 2009-04-22 2012-10-18 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ モノアシルグリセロールリパーゼ阻害剤としてのアゼチジニルジアミド
FR2945531A1 (fr) 2009-05-12 2010-11-19 Sanofi Aventis Derives de 7-aza-spiro°3,5!nonane-7-carboxylates, leur preparation et leur application en therapeutique
JPWO2011142359A1 (ja) 2010-05-10 2013-07-22 日産化学工業株式会社 スピロ化合物及びアディポネクチン受容体活性化薬
FR2960875B1 (fr) 2010-06-04 2012-12-28 Sanofi Aventis Derives de carbamates d'hexafluoroisopropyle, leur preparation et leur application en therapeutique
CA2810077A1 (en) 2010-09-27 2012-04-05 Peter J. Connolly Oxopiperazine-azetidine amides and oxodiazepine-azetidine amides as monoacylglycerol lipase inhibitors
BR112013009828A2 (pt) 2010-10-22 2016-07-26 Janssen Pharmaceutica Nv diamidas de amino-pirrolidina-azetidina como inibidores de monoacilglicerol lipase
US8513423B2 (en) 2010-10-22 2013-08-20 Janssen Pharmaceutica, Nv Piperidin-4-yl-azetidine diamides as monoacylglycerol lipase inhibitors
CN103517910B (zh) 2011-03-14 2016-12-14 沃泰克斯药物股份有限公司 作为离子通道调节剂的吗啉-螺环哌啶酰胺
JP2014159376A (ja) 2011-06-17 2014-09-04 Taisho Pharmaceutical Co Ltd アザスピロアルカン化合物
WO2013131010A2 (en) 2012-03-02 2013-09-06 Icahn School Of Medicine At Mount Sinai Function of chemokine receptor ccr8 in melanoma metastasis
WO2014012054A1 (en) 2012-07-13 2014-01-16 Pain Therapeutics, Inc. Alzheimer's disease assay in a living patent
WO2014074715A1 (en) 2012-11-07 2014-05-15 Genentech, Inc. Cyclopropyl amide derivatives
WO2015104343A1 (en) 2014-01-09 2015-07-16 Proyecto De Biomedicina Cima, S.L. New antifibrinolytic compounds
UA121775C2 (uk) 2015-07-31 2020-07-27 Пфайзер Інк. 1,1,1-трифтор-3-гідроксипропан-2-ілкарбаматні похідні та 1,1,1-трифтор-4-гідроксибутан-2-ілкарбаматні похідні як інгібітори magl
WO2017197192A1 (en) * 2016-05-12 2017-11-16 Abide Therapeutics, Inc. Spirocycle compounds and methods of making and using same

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2553451C2 (ru) * 2008-12-24 2015-06-20 Биал-Портела Энд Ка, С.А. Фармацевтические соединения
WO2013103973A1 (en) * 2012-01-06 2013-07-11 Abide Therapeutics Carbamate compounds and of making and using same
US9133148B2 (en) * 2012-01-06 2015-09-15 The Scripps Research Institute Carbamate compounds and of making and using same
WO2016149401A2 (en) * 2015-03-18 2016-09-22 Abide Therapeutics, Inc. Piperazine carbamates and methods of making and using same

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Patel, J. Z., Ahenkorah, S., Vaara, M., Staszewski, M., Adams, Y., Laitinen, T. Nevalainen, T. J. (2015). Loratadine analogues as MAGL inhibitors. Bioorganic & Medicinal Chemistry Letters, 25(7), 1436-1442. doi:10.1016/j.bmcl.2015.02.037. *

Also Published As

Publication number Publication date
JP2020506903A (ja) 2020-03-05
US10858373B2 (en) 2020-12-08
EP3571202A1 (en) 2019-11-27
EP3571202B1 (en) 2021-06-30
BR112019014099A2 (pt) 2020-02-11
WO2018134698A1 (en) 2018-07-26
AU2018208848A1 (en) 2019-07-18
TWI665199B (zh) 2019-07-11
US20180208608A1 (en) 2018-07-26
IL267781A (en) 2019-09-26
SG11201906427QA (en) 2019-08-27
CA3050853A1 (en) 2018-07-26
MX2019008690A (es) 2019-09-18
TW201838995A (zh) 2018-11-01
KR20190097242A (ko) 2019-08-20
US20190292203A1 (en) 2019-09-26
CN110198944A (zh) 2019-09-03

Similar Documents

Publication Publication Date Title
RU2726631C1 (ru) Гетероциклические спиросоединения в качестве ингибиторов magl
US10723711B2 (en) 1,1,1-trifluoro-3-hydroxypropan-2-yl carbamate derivatives and 1,1,1-trifluoro-4-hydroxybutan-2-yl carbamate derivatives as MAGL inhibitors
US10626125B2 (en) 1,1,1-trifluoro-3-hydroxypropan-2-yl carbamate derivatives as MAGL inhibitors
HK40006064A (en) Heterocyclic spiro compounds as magl inhibitors
HK40012422A (en) 1,1,1-trifluoro-3-hydroxypropan-2-yl carbamate derivatives as magl inhibitors